The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

The approval of Zepbound for obstructive sleep apnea treatment is based on the results of two major studies from the SURMOUNT ... remission or a reduction to mild OSA, compared with just 14 ...

reports a new study. This is the first time breathing rhythms during ... Sleep Apnea Contributes to Dementia in Older Adults, Especially Women Oct. 31, 2024 — Sleep apnea, a common yet ...

Study participants who took Zepbound also achieved remission or mild obstructive sleep apnea at a greater proportion than the placebo group. These results were observed among those who do and do ...

Friday's FDA approval of Zepbound for treating moderate to severe sleep apnea came after the SURMOUNT-OSA phase 3 clinical trials -- two randomized, double-blind, placebo-controlled studies of 469 ...

Dec. 20, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with ...

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea ... In these studies, the drug ...

In both studies ... obstructive sleep apnea with obesity," researchers wrote in the New England Journal of Medicine.The most common side effects were gastrointestinal events, which were typically ...